← 產業報告目錄
Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report, by Therapeutic Area (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN), by Dosage Form, by Type of Immunoglobulin, End User, By Region, Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-18頁數 180報告編號 INSIGHTACE-9f81cbdf7d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 13.26 billion as of 2024, the global Intravenous Immunoglobulin Market is expected to climb to USD 25.46 billion by 2034, reflecting a compound annual growth rate of 7.0% over the 2025–2034 period.
At its core, Intravenous Immunoglobulin pertains to glycoprotein molecules produced by plasma or white blood cells. Stakeholders across the healthcare landscape are risingly turning to these solutions to meet contemporary demands.
The market's upward path is supported by rising healthcare spending, technological evolution, and the rising focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Intravenous Immunoglobulin Market Snapshot
Chapter 4. Global Intravenous Immunoglobulin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapeutic Area Estimates & Trend Analysis
5.1. by Therapeutic Area & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:
5.2.1. Primary Immunodeficiency
5.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2.3. Guillain-Barré Syndrome (GBS)
5.2.4. Immune Thrombocytopenic Purpura (ITP)
5.2.5. Multifocal Motor Neuropathy (MMN)
Chapter 6. Market Segmentation 2: by Dosage Form Estimates & Trend Analysis
6.1. by Dosage Form & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Dosage Form:
6.2.1. Liquid
6.2.2. Lyophilized
Chapter 7. Market Segmentation 3: by Immunoglobulin Estimates & Trend Analysis
7.1. by Immunoglobulin & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Immunoglobulin:
7.2.1. IgG
7.2.2. IgA
7.2.3. IgM
7.2.4. IgE
7.2.5. IgD
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Homecare
8.2.4. Other End Users
Chapter 9. Intravenous Immunoglobulin Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.1.2. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.1.3. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.1.4. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.1.5. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.2.2. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.2.3. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.2.4. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.2.5. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.3.2. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.3.3. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.3.4. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3.5. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.4.2. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.4.3. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.4.4. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4.5. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.5.2. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.5.3. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.5.4. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5.5. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Bio Products Laboratory
10.2.2. Biotest
10.2.3. China biologics Products Holdings
10.2.4. CSL Behring
10.2.5. Grifols
10.2.6. Kedrion
10.2.7. LFB
10.2.8. Octapharma
10.2.9. Shanghai RAAS Blood products
10.2.10. Shire
10.2.11. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們